Los Angeles Capital Management LLC lifted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 11.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 89,741 shares of the company’s stock after acquiring an additional 9,380 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Medpace were worth $52,083,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the business. Optiver Holding B.V. bought a new stake in Medpace during the 3rd quarter valued at $27,000. Geneos Wealth Management Inc. raised its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace during the 4th quarter valued at $30,000. Elyxium Wealth LLC bought a new stake in Medpace during the 4th quarter valued at $30,000. Finally, Quarry LP bought a new stake in Medpace during the 3rd quarter valued at $35,000. 77.98% of the stock is currently owned by institutional investors.
Medpace Trading Down 1.0%
Shares of NASDAQ MEDP opened at $454.25 on Friday. Medpace Holdings, Inc. has a 12 month low of $294.07 and a 12 month high of $628.92. The firm has a market capitalization of $12.97 billion, a PE ratio of 28.55, a price-to-earnings-growth ratio of 2.30 and a beta of 1.18. The firm has a fifty day simple moving average of $456.73 and a two-hundred day simple moving average of $508.93.
Insider Buying and Selling at Medpace
In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares of the company’s stock, valued at $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 20.50% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on MEDP. Mizuho set a $582.00 price target on shares of Medpace in a report on Wednesday, February 11th. Truist Financial lowered their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a report on Wednesday, February 11th. Weiss Ratings lowered shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a report on Friday, February 13th. Finally, Barclays lowered their price target on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $467.08.
Get Our Latest Stock Report on Medpace
Medpace News Summary
Here are the key news stories impacting Medpace this week:
- Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
- Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
- Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title
Medpace Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Stories
- Five stocks we like better than Medpace
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
